跳至主要内容
临床试验/NCT05828732
NCT05828732招募中不适用

Clinical Feasibility of Disease-managing Mobile Application in the Patients With Hyperthyroidism

Seoul National University Bundang Hospital2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
2
主要终点
Scores of quality of life assessed by SF-36 survey

研究概览

简要总结

This randomized controlled study aims to investigate the effects of using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. The study intends to evaluate how the use of the app affects disease progression, quality of life, and health-related behaviors associated with the disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who have been newly diagnosed or are currently undergoing treatment for thyrotoxicosis at Bundang Seoul National University Hospital.
  • Subjects must be able to use the smartphone app required for the use of wearable devices and their integration.

排除标准

  • Subjects who have constraints on normal activity due to diseases other than thyroid dysfunction.
  • Subjects who are currently taking medication that affects heart rate.
  • Subjects with heart conditions such as arrhythmia that affect heart rate.
  • Subjects who cannot undergo antithyroid drug treatment and require surgery or radioactive iodine therapy.

结局指标

主要结局

Scores of quality of life assessed by SF-36 survey

时间窗: 14 weeks after baseline

Scores of quality of life assessed by SF-36 survey

antithyroidal drug compliance

时间窗: 14 weeks after baseline

Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.

Knowledge about hyperthyroidism

时间窗: 14 weeks after baseline

A score measured through a test designed to assess the knowledge level about Graves' disease

次要结局

  • free T4(14 weeks after baseline)
  • free T3(14 weeks after baseline)
  • TSH(14 weeks after baseline)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jae Hoon Moon

Professor

Seoul National University Bundang Hospital

研究点 (2)

Loading locations...

相似试验

Clinical Feasibility of Disease Managing Mobile App... | 临床试验